Immunomedics, Inc.

NASDAQ:IMMU   3:59:55 PM EDT
87.86
+0.04 (+0.05%)
Products

Immunomedics Announces FDA Orphan Drug Designation Of Trodelvy For Adult And Pediatric Glioblastoma

Published: 10/12/2020 13:07 GMT
Immunomedics Inc (IMMU) - Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma.
Immunomedics - Office of Orphan Products Development of U.S. FDA Has Granted Trodelvy Orphan Status for Treatment of Patients With Glioblastoma.